Cargando…
Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target
BACKGROUND: Drug resistance and the lack of molecular therapeutic target are the main challenges in the management of osteosarcomas (OSs). Identification of novel genetic alteration(s) related with OS recurrence and chemotherapeutic resistance would be of scientific and clinical significance. METHOD...
Autores principales: | Nie, Jun-Hua, Yang, Tao, Li, Hong, Ye, Hai-Shan, Zhong, Guo-Qing, Li, Ting-Ting, Zhang, Chi, Huang, Wen-Han, Xiao, Jin, Li, Zhi, He, Jian-Li, Du, Bo-Le, Zhang, Yu, Liu, Jia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476350/ https://www.ncbi.nlm.nih.gov/pubmed/34611509 http://dx.doi.org/10.1016/j.jbo.2021.100391 |
Ejemplares similares
-
Frequently expressed glypican‐3 as a promising novel therapeutic target for osteosarcomas
por: Nie, Jun‐Hua, et al.
Publicado: (2022) -
ENGINEERING T CELLS TARGETING GPC2 FOR TREATING NEUROBLASTOMA
por: Quan, Alex, et al.
Publicado: (2023) -
GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer
por: Chen, Guoming, et al.
Publicado: (2022) -
Somatic glypican 3 (GPC3) mutations in Wilms' tumour
por: White, G R M, et al.
Publicado: (2002) -
GPC1 Is Associated with Poor Prognosis and Treg Infiltration in Colon Adenocarcinoma
por: Liu, Ying, et al.
Publicado: (2022)